Physician profile
Aamer Shabbir
NPI 1740242163
$3,761.87
in general payments reported to CMS, 2019-2025
28 companies · $724 in 2025
The $724 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $729 · 2020: $503 · 2021: $532 · 2022: $621 · 2023: $361 · 2024: $292 · 2025: $724.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,357 · Education: $20.22.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,356.78 |
| Education | $20.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $544.67 | 2019-2025 | Lifevest |
| Novartis Pharmaceuticals Corporation | $461.83 | 2019-2024 | |
| Boston Scientific Corporation | $399.77 | 2019-2025 | Ekosonic, Lux-Dx Insertable Cardiac Monitor, Watchman Flx |
| Medtronic Vascular, INC. | $322.95 | 2019-2020 | |
| Pfizer INC. | $215.70 | 2022-2025 | |
| Heartflow, INC. | $180.10 | 2025 | |
| Janssen Pharmaceuticals, INC | $177.58 | 2019-2024 | Xarelto |
| Boehringer Ingelheim Pharmaceuticals, INC. | $163.90 | 2019-2024 | Jardiance |
| Astrazeneca Pharmaceuticals LP | $158.90 | 2019-2022 | |
| Shockwave Medical, INC | $149.81 | 2025 | |
| Actelion Pharmaceuticals US, INC. | $139.60 | 2019-2025 | Opsumit, Uptravi |
| Abiomed | $135.85 | 2024-2025 | Impella |
| Abbott Laboratories | $132.88 | 2022-2023 | Thoratec Heartmate 3 Lvas Implant Kit |
| United Therapeutics Corporation | $98.06 | 2023 | Tyvaso |
| E.R. Squibb & Sons, L.L.C. | $81.44 | 2019-2025 | Camzyos, Eliquis |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amarin Pharma, INC. | $57.33 | 2019-2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $48.35 | 2021-2025 | |
| Amgen INC. | $47.87 | 2019-2021 | |
| Vifor Pharma, INC. | $38.15 | 2022 | |
| Esperion Therapeutics, INC. | $28.71 | 2021 | |
| Kestra Medical Technology Services, INC. | $28.63 | 2025 | Assure Wcd |
| Regeneron Healthcare Solutions, INC. | $27.64 | 2019 | |
| Novo Nordisk INC | $27.53 | 2021 | |
| Baxter Healthcare | $23.11 | 2022 | |
| Medtronic, INC. | $21.58 | 2021 | |
| Electromed, INC. | $19.81 | 2025 | Smartvest |
| Philips North America LLC | $15.26 | 2025 | Holter |
| Glaxosmithkline, LLC. | $14.86 | 2025 | Shingrix |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Aamer Shabbir listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.